Assoc Medical Director, Complement - United States
The Associate Medical Director will support the Medical Director in providing strategic planning and leadership to all in-country Medical Affairs activities for Alexion’s complement inhibitor franchise, including a marketed product (Soliris) to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), and a late stage investigational therapeutic complement inhibitor (ALXN1210) in phase 3 for PNH and aHUS.
The Associate Medical Director will advance the understanding of the medical landscape in relation to complement activation disorders and treatment, and support the development and implementation of appropriate strategies within the country aligned with the Global Medical Affairs strategy for the complement franchise. These activities include, but are not limited to, life cycle management data generation, publications, scientific exchange, advisory boards, medical insights, and thought leader development.
- Define the country Medical resource needs, and manage budget planning and resource allocation
- Support U.S. Medical Director in leading monthly and quarterly reviews of US medical affairs activities, including field medical activities
- Conduct Ad Boards, develop and maintain relationships with top thought leaders, and utilize medical insights from the field teams to inform the Medical Product Plan.
- Deliver and execute local Medical Product Plan aligned with Global Medical Product Plan.
- Ensure timely Country Publication Planning and Communication activities in supportive of Global Medical Affairs strategy.
- Identify and implement appropriate high-impact medical research projects to support the strategic objectives, including Alexion–sponsored and investigator initiated projects
- Collaborate with global medical education team to localize (and develop as needed) medical content for scientific exchange by field medical team.
- Provide appropriate and timely medical affairs support to key commercial and reimbursement activities aligned with strategic priorities.
- Review and approve promotional materials to ensure information is accurate, relevant to the Country environment, and ensure medical accuracy.
- Support medical information function, ensure timely response to medical information inquiries and collation of requests, utilizing global medical information resources and in line with local regulatory requirements and company policy.
- Ensure effective team communication, performance and documentation of medical affairs activities and knowledge through the application of suitable reporting systems and structures
- Identifying training needs in collaboration with key stakeholders and ensure implementation of medical training programs for the field medical team as well as other cross-functional members as appropriate.
- Collaborate with Clinical Operations to manage the in country Clinical Operations Lead role and ensuring their activities are prioritized to meet the clinical operations and country objectives.
- Minimum of 2+ years in medical affairs
- Product lifecycle management experience preferred
- Orphan diseases knowledge/experience preferred but not required
- Demonstrated ability to create and lead successful cross-functional teams in changing, competitive environments
- Demonstrated ability to influence important customers, challenge common perceptions and implement medical affairs tools to improve patient care and outcomes
- Good analytical skills as applied to medical, scientific and technical information.
- Demonstrated ability to accurately and effectively evaluate medical/scientific literature and develop effective medical strategies and communication strategies.
- Demonstrated experience in early and late clinical development.
- Excellent written and verbal communication skills in both local language and in English
- Adaptability to multicultural environment
- Medical degree (M.D.), Pharm D or Ph D
Lexington, MA, United States
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed and commercializes Soliris® (eculizumab), the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders. As the global leader in complement inhibition, Alexion is strengthening and broadening its portfolio of complement inhibitors, including evaluating potential indications for eculizumab in additional severe and ultra-rare disorders. Alexion’s metabolic franchise includes two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare disorders, Strensiq® (asfotase alfa) to treat patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) to treat patients with lysosomal acid lipase deficiency (LAL-D). In addition, Alexion is advancing the most robust rare disease pipeline in the biotech industry, with highly innovative product candidates in multiple therapeutic areas.
As a leading employer in our industry, Alexion is proud to offer a highly competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, 401(k) with company match, tuition reimbursement, relocation assistance and much more. To learn more about Alexion, please visit www.alexionpharma.com or download our App for iPhones and Blackberries.
Alexion is an Equal Opportunity /Affirmative action employer